This clinical-stage biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Wednesday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
ArQule currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Med-drugs industry may consider Cempra, Inc. (CEMP) that sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment